

Industry Therapeutic Update from Sanofi Medical

*An Evolving  
Paradigm:  
Challenging  
the Approach to  
Disability in MS*

**Tuesday April 8th, 11:45 AM PDT  
Room 6B, San Diego Convention Center**

Doors open at 11:15 AM PDT  
Lunch will be served

# *Agenda*

**Scott Newsome**  
**DO, MSCS, FAAN**

*Detecting Disability in the Clinic*

**Daniel Ontaneda**  
**MD, PhD, FAAN**

*Imaging Markers and Disability*

**Jiwon Oh**  
**MD, PhD, FRCPC**

*Impacting the Biology of  
Disability Accumulation*

**Live Q&A**

As the science of MS advances, the understanding of disability is continuing to evolve. In this Sanofi Medical Industry Therapeutic Update, MS experts will discuss developments in this area, including recent scientific data that may impact future directions for clinical practice.



Join us at the 2025 AAN Annual Meeting for an exciting discussion and the opportunity to ask your questions in a live Q&A at the end of the session.



***Scott Newsome***  
**DO, MSCS, FAAN**

*Professor of Neurology,  
Division of Neuroimmunology and  
Neurological Infections, Johns Hopkins*

*Director, Neurosciences Consultation  
and Infusion Center*

*Director, Stiff Person Syndrome Center*

*Director, Neuroimmunology and Neurological  
Infectious Disease Fellowship Program*

*Co-Director, MS Experimental Therapeutics Program*

He has special interest in evaluating and treating people with MS, transverse myelitis, neuromyelitis optica spectrum disorder, and stiff person syndrome. Dr. Newsome joined the division of Neuroimmunology and Neurological Infections at Johns Hopkins after completing a neuroimmunology fellowship at The Johns Hopkins Hospital with the support of a Sylvia Lawry Physician Fellowship from the National MS Society.

Dr. Newsome's main research focuses on helping identify and test novel therapies and therapeutic strategies in MS and other neuroimmunological disorders. In addition, other research endeavors include identifying risk factors of disease onset and severity, response to treatment, and long-term outcomes in neuroimmunological disorders. Dr. Newsome is also Past-President of the Consortium of MS Centers, an advisor for the National MS Society, a steering committee member of the International MS Differential Diagnosis Consortium, Founder and Chair of the International Stiff Person Syndrome Consortium, and a member of the Miller-Coulson Academy of Clinical Excellence.

***Daniel Ontaneda***  
**MD, PhD, FAAN**

*Professor of Neurology, Cleveland Clinic  
Lerner College of Medicine  
of Case Western Reserve University*

*Staff Neurologist, Cleveland Clinic  
Neurological Institute's Mellen  
Center for MS*

*Director of Research, Mellen Center for MS*



His research focuses on imaging outcome measures for MS and imaging-based clinical trials. He is an ACTRIMS board member, a member of the Executive Steering Committee for the NAIMS and the LACTRIMS, and has served on the International Advisory Committee on Clinical Trials in MS.

Dr. Ontaneda's research is funded by the National Institutes of Health, National MS Society, Race to Erase Foundation, Department of Defense, and Patient Centered Outcomes Research Institute. Dr. Ontaneda was the recipient of a Sylvia Lawry National MS Society clinical Fellowship Award and a National Institutes of Health KL2 CTSA career transition award. Dr. Ontaneda is a fellow of the AAN and is a member of the editorial boards for JAMA Neurology and Multiple Sclerosis Journal.

***Jiwon Oh***  
**MD, PhD, FRCPC**

*Medical Director, Barlo MS Program*

*Associate Professor, Division of  
Neurology, St. Michael's Hospital,  
University of Toronto*

*Staff Neurologist, St. Michael's Hospital*

*Scientist, Keenan Research Centre of the  
Li Ka Shing Knowledge Institute*



Dr. Oh's research focuses on developing advanced MRI techniques for use in clinical settings, and the development of large datasets. She leads the MRI research program at St. Michael's Hospital and is the principal investigator on numerous local and multi-center collaborative studies, including the CanProCo, which is a national Canadian prospective cohort study designed to better understand progression in MS. Dr. Oh is one of the founding members of the NAIMS representing a multi-national collaborative MRI research endeavor in MS with over 40 sites in North America.

She cares for a large practice of people living with MS and has overseen the development of the Barlo MS program into a thriving clinical and research program. She is deeply committed to caring for people with MS, educating future generations of clinicians and scientists, and contributing to scientific developments that will drive the field forward.



**Your feedback is important.**

Click the link below to participate in  
polling questions and share your  
feedback on the Industry Therapeutic  
Update from Sanofi Medical.

**Share your feedback**

All responses are anonymous.

This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

MAT-GLB-2500031 – 2.0 – 03/2025

©2025 Sanofi. All rights reserved.  
Sanofi is a registered trademark of Sanofi or an affiliate.